10x Genomics, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 2, 2022, 20:43 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $131.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $360.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $30.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $83.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $100.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $276.6m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $73.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $219.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$40.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$144.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $114.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $351.0k | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $1.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $3.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$41.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$148.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$1.31 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$1.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 114,112,382 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 113,555,750 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$47.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $91.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2022-09-30 | $629.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $996.2m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $126.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $220.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $775.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001770787-22-000057. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.